Tower Research Capital LLC (Trc) Allogene Therapeutics, Inc. Transaction History
Tower Research Capital LLC (Trc)
- $3.68 Billion
- Q3 2024
A detailed history of Tower Research Capital LLC (Trc) transactions in Allogene Therapeutics, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 5,375 shares of ALLO stock, worth $7,955. This represents 0.0% of its overall portfolio holdings.
Number of Shares
5,375
Previous 31,585
82.98%
Holding current value
$7,955
Previous $73,000
79.45%
% of portfolio
0.0%
Previous 0.0%
Shares
22 transactions
Others Institutions Holding ALLO
# of Institutions
166Shares Held
133MCall Options Held
59.4KPut Options Held
113K-
Tpg Gp A, LLC Fort Worth, TX18.7MShares$27.7 Million1.25% of portfolio
-
Black Rock Inc. New York, NY16.4MShares$24.3 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8MShares$11.8 Million0.0% of portfolio
-
State Street Corp Boston, MA7.01MShares$10.4 Million0.0% of portfolio
-
Capital World Investors Los Angeles, CA6.9MShares$10.2 Million0.0% of portfolio
About Allogene Therapeutics, Inc.
- Ticker ALLO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 143,807,008
- Market Cap $213M
- Description
- Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...